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536 Abstracts
using ABI Info, EconLit, PsychInfo, MEDLINE, 
CANCERLIT, AIDSLINE, HealthStar; databases were
searched from 1990–2001. Articles identiﬁed comprised
productivity measured by subjective (self-report ques-
tionnaires) and objective (computer-based tracking
systems) techniques; subjective instruments included both
generic and disease-speciﬁc measures. Identiﬁed instru-
ments were evaluated on psychometric properties, 
generalizability to different populations, and administra-
tor/respondent burden. RESULTS: Five generic subjective
measures were identiﬁed—the Endicott Work Produc-
tivity Scale; Health and Labor Questionnaire; Health and
Work Questionnaire; Work Limitations Questionnaire;
and the Work Productivity and Activity Impairment
Questionnaire (WPAI)—that could theoretically be used
in any working population. All subjective instruments
showed adequate to good reliability. However, these
instruments were usually validated against other subjec-
tive measures (such as health-related quality of life), as a
uniform measure of “productivity” does not exist. The
WPAI was the most frequently used instrument and has
also been modiﬁed to measure productivity reductions
associated with speciﬁc diseases (e.g., allergic rhinitis,
gastro-esophageal reﬂux disease). Objective assessments
have been carried out to measure employee productivity
for tasks where individual output could be quantiﬁed
(e.g., claims processed, telephone inquiries handled). To
avoid respondent bias, these studies utilized computer-
based tracking systems to determine productivity reduc-
tion attributable to illness. CONCLUSIONS: Subjective
and objective productivity assessments offer different
beneﬁts: while subjective instruments can be used in 
populations with different illnesses and/or jobs, objective
measures minimize respondent bias but are associated
with restricted generalizability and are burdensome to
carry out in practice.
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OBJECTIVE: Allogeneic stem cell transplantations 
(SCT) for leukaemias are known to be one of the most
expensive medical procedures. In the Netherlands, a 
few licensed hospitals perform allogeneic SCT. However,
the budgets they receive are not sufﬁcient (for instance
due to the application of donor lymphocyte infusions).
We calculated the direct medical costs of patients 
who underwent allogeneic SCT to support a budget 
revision. METHODS: Costs of HLA-identical sibling
bone marrow transplantation (BMT), bone marrow
transplantation from a Matched Unrelated Donor (MUD)
and peripheral blood stem cell transplantation (PBSCT)
were identiﬁed. Costs were determined by two comple-
mentary methods. First, medical consumption for these
patients was determined and multiplied by the unit costs
of each of the items. Second, a structural program for
allogeneic transplantations brings along costs that are not
expressed in the registration of the medical consumption
of patients (e.g. HLA-typing and selection of the unre-
lated donor). The costs of these items were identiﬁed in
cooperation with the ﬁnancial departments of the hospi-
tals, and by expert opinion. RESULTS: The average costs
per transplanted patient were €98,334 (BMT), €151,754
(MUD), and €98,977 (PBSCT) for a follow-up period of
2 years. This includes the costs of hospitalizations,
medical procedures, medication, donor identiﬁcation and
the costs of patients who were not transplanted after they
had been planned to receive an allograft. The majority of
costs were made prior to and during hospitalization for
graft infusion. In MUD transplantation the costs of
ﬁnding a suitable donor comprise nearly one third of total
costs. CONCLUSION: This cost analysis gives a proper
indication of the costs associated with performing differ-
ent types of allogeneic SCTs and maintaining a structural
transplantation program in the Netherlands. The results
of this analysis will be used in determining a new budget
for allogeneic SCTs in the Netherlands.
PCN2
COST-EFFECTIVENESS OF NEW CERVICAL
CANCER SCREENING TECHNOLOGIES:A
GERMAN HEALTH TECHNOLOGY ASSESSMENT
AND DECISION-ANALYSIS
Sroczynski G1, Siebert U1,Voigt K2, Gibis B3,Aidelsburger P4,
Wasem J4, Hillemanns P2, Engel J2, Hölzel D2, Goldie S1
1Harvard School of Public Health, Boston, MA, USA;
2University Munich, Munich, Germany; 3National Association
of Statutory Health Insurance Physicians, Berlin, Germany;
4University of Greifswald, Greifswald, Germany
OBJECTIVES: The objective of this health technology
assessment commissioned by the German Agency for
Health Technology Assessment at DIMDI/German
Federal Ministry of Health was to conduct a systematic
review of the cost-effectiveness of new cervical cancer
screening techniques, and to perform a decision-analysis
in the context of the German health care system.
METHODS: A systematic literature review and assess-
ment on quality/transferability of data was performed
using instruments developed by the German Scientiﬁc
